Showing 5081-5090 of 8889 results for "".
- Study: AD Patients Switching From Dupilumab to Upadacitinib Have Improved EASI, Itch Scoreshttps://practicaldermatology.com/news/Study-AD-Patients-Switching-From-Dupilumab-Upadacitinib-Have-Improved-EASI-Itch-Scores/2474207/Treatment of moderate-to-severe atopic dermatitis (AD) with upadacitinib in patients who received dupilumab for 16 weeks without an adequate response demonstrated improved efficacy in skin and itch endpoints, according to new research. “Switching from Dupilumab to Upadacitinib in Adults an
- Metabolomic Signature Predictive of Ocular Side Effects in Dupilumab-Treated AD: Studyhttps://practicaldermatology.com/news/metabolomic-signature-may-predict-ocular-side-effects-in-dupilumab-treated-atopic-dermatitis-study/2474199/New research suggests baseline metabolic differences may help predict which patients with atopic dermatitis (AD) are most likely to develop ocular complications from dupilumab. In findings published in
- Pelthos Therapeutics and Channel Therapeutics to Mergehttps://practicaldermatology.com/news/pelthos-therapeutics-and-channel-therapeutics-to-merge/2474190/Ligand Pharmaceuticals has announced a definitive merger agreement that will combine its wholly owned subsidiary Pelthos Therapeutics with Channel Therapeutics Corporation, forming a publicly traded company under the name Pelthos Therapeutics Inc. The deal is suppo
- Biologic Costs for Plaque Psoriasis Doubled Since 2007, Study Findshttps://practicaldermatology.com/news/biologic-costs-for-plaque-psoriasis-double-since-2007-study-finds/2474189/A new analysis shows the average net annual cost of first-line biologic treatments for plaque psoriasis more than doubled between 2007 and 2021, rising from $21,236 to $47,125. The study researchers, publishing online in J
- Review Unpacks Safety Data in Psoriasis Trialshttps://practicaldermatology.com/news/review-unpacks-safety-data-in-psoriasis-trials/2474174/While clinical trials frequently emphasize efficacy, safety data often remain inconsistently analyzed and underreported, according to the authors of a new review in the Journal of Clinical and Aesthetic Dermatology.
- Study: Strontium May Help Alleviate Pruritus for HS Patientshttps://practicaldermatology.com/news/Study-Strontium-May-Help-Alleviate-Pruritus-HS-Patients/2474128/Strontium cream demonstrated promise as a therapeutic option for managing pruritus in hidradenitis suppurativa (HS), according to a new research article published in the Journal of Clinical and Aesthetic Dermatology. In a prospective, open-label, real-world study involving 50 part
- Melanoma Risk Model Validated in Global Studyhttps://practicaldermatology.com/news/international-study-strengthens-confidence-in-sentinel-node-prediction-tool/2474126/The Melanoma Institute Australia (MIA) sentinel node (SN) metastasis risk calculator has been validated in a large, multinational cohort, reinforcing its applicability across diverse populations and clinical settings. The MIA
- Study Links Psoriasis Gene Regulation to Spatial Genome Changeshttps://practicaldermatology.com/news/study-links-psoriasis-gene-regulation-to-spatial-genome-changes/2474007/Results from a new study in the Journal of Investigative Dermatology showed how changes in the 3D chromatin architecture of CD4+ T cells contribute to immune dysregulation in psoriasis. "In this study, the 3D genomic
- Study: Dermabrasion Trials Rarely Report Race or Skin Typehttps://practicaldermatology.com/news/study-dermabrasion-trials-rarely-report-race-or-skin-type/2474005/Most clinical trials studying dermabrasion have failed to report racial or skin-type demographics, according to a new systematic review. "Clinical trials that are racially homogenous or do not report race limit the generalizab
- AI Assists in Creating Aesthetic Injector Training Programhttps://practicaldermatology.com/news/ai-assists-in-creating-aesthetic-injector-training-program/2473956/Artificial intelligence was reported as significantly useful in developing an educational course for facial botulinum toxin injections, according to a new study in Journal of Drugs in Dermatology.